Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression".
Matthew B Roberts, Jay A Fishman
https://pubmed.ncbi.nlm.nih.gov/32803228/Actively Recruiting
Led by Hospital Italiano de Buenos Aires · Updated on 2026-10-15
60
Participants Needed
3
Research Sites
47 weeks
Total Duration
Researchers are conducting a multicenter, prospective observational study involving adults undergoing liver transplantation to evaluate immune biomarkers. The study aims to describe how immune markers change before and after transplantation and to explore their relationship with complications such as infections, acute cellular rejection, and viral reactivation within the first year following transplantation. This research is carried out at three liver transplant centers in Buenos Aires, Argentina. Participants will have blood samples collected before transplantation, on days 0, 3, and 7 after transplantation, and then at months 1, 3, 6, and 12. These samples will be tested for various immune biomarkers including cytokines, interferons, immunoglobulins, lymphocyte populations, monocyte HLA-DR, neutrophil CD64, functional immune assays, checkpoint molecules, and Torque Teno Virus. The study groups include liver transplant recipients with immune-mediated liver disease and those with non-immune-mediated liver disease. All biomarker measurements are for research only and will not influence clinical decisions or immunosuppressive therapy. During the study, participants will be monitored prospectively for clinical outcomes such as infections, acute cellular rejection, hospitalizations, and viral reactivations. Researchers will analyze the biomarker changes over time and their association with these outcomes, assessing their potential usefulness in diagnosis and prediction. The study lasts for 12 months after transplantation, with multiple blood collection visits and clinical follow-up to track participants health and immune status.
CONDITIONS
Immune Biomarkers for Predicting Complications After Liver Transplantation
J
Jorge Martinez, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hospital Italiano de Buenos Aires
Lead Sponsor
Austral University, Argentina
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - 12 months
Participants have blood samples collected before transplantation, on days 0, 3, and 7, and at months 1, 3, 6, and 12 after transplantation. Clinical outcomes are monitored during this period.
Multiple visits for blood collection and clinical assessments
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Matthew B Roberts, Jay A Fishman
https://pubmed.ncbi.nlm.nih.gov/32803228/Niv Reiss-Gindi, Tomer Hoffman, Tanya Ruderman...
https://pubmed.ncbi.nlm.nih.gov/39576569/Bo Peng, Min Yang, Quan Zhuang...
https://pubmed.ncbi.nlm.nih.gov/36505404/Kevin Louis, Tracy Tabib, Camila Macedo...
https://pubmed.ncbi.nlm.nih.gov/39419342/Adam G Stewart, Camille N Kotton
https://pubmed.ncbi.nlm.nih.gov/37899366/J W Haveman, A P van den Berg, J M van den Berk...
https://pubmed.ncbi.nlm.nih.gov/11428984/Thomas F Patterson, George R Thompson, David W Denning...
https://pubmed.ncbi.nlm.nih.gov/27365388/Jon Salmanton-García, Alessandro Giacinta, Maddalena Giannella...
https://pubmed.ncbi.nlm.nih.gov/40614031/Sebastián Marciano, Jorge Carlos Martínez Morales, Camila Juana...
https://pubmed.ncbi.nlm.nih.gov/39079129/Pablo Ruiz, Marta Martínez-Picola, Miguel Santana...
https://pubmed.ncbi.nlm.nih.gov/30375165/Hospital Italiano de Buenos Aires
Lead Sponsor
Austral University, Argentina
Collaborating Sponsor